ACTOnco®+  Comprehensive Genomic Profiling for Solid Tumors


| Find the Right Treatment For The Right Patient: ACTOnco® + is an NGS-based test developed to support and answer the clinical challenges faced during the management of solid tumors, including carcinomas, sarcomas, and lymphomas. The ACTOnco+® comprises 440 specially-curated genes, 13 fusion genes with more than 350 fusion transcripts. It references the Hallmarks of Cancer to facilitating treatment strategies, which include chemotherapy, targeted therapy, immunotherapy, and pharmacogenomics. | Key Features: Comprehensive pathway-based Panel: Sequencing of 440 cancer-related genes and 13 fusion genes & more than 350 fusion transcripts covering most key cancer signaling pathways for targeted therapy Predicting immunotherapy response: Incorporating mutation burden, immune-related gene information, and MSI for a more accurate immunotherapy recommendation Pharmacogenetics information: Responses to treatments may be affected by inherited genetic variations (polymorphisms). Pharmacogenetics information can be used to match patients with the treatment that is most effective while causing fewer side effects. Providing Report Consultation: Every report is complemented with a face-to-face/phone consultation with our medical team. Suitable for Most Patients: - Newly diagnosed with complex cancer type - Recurrent and metastatic cases - Patient searching for treatment (and trials) options - Diagnosed with advanced cancer or late-stage cancer Short Turnaround Time: Providing a testing report in 10 working days.
Visit ID (prod)
ACT Genomics Co. Ltd.(Looking for distributors) Company IntroACT Genomics is a leading cancer genomic testing provider started in Taiwan in 2014. Now, we have grown and expanded into Japan, Singapore, Hong Kong, and the Southeast Asia region.With cutting-edge next-generation sequencing (NGS), proprietary bioinformatics analysis, and combined expertise in tumor biology, cancer genomics, bioinformatics, and artificial intelligence, our genomic tests provide treatment suggestions based on the tumor's genomic markup. With our tests, the doctors can formulate a personalized treatment plan to achieve a better outcome for their cancer patients.Our NGS-based TestsACTOnco® +: Tumor tissue-based (FFPE)Provides comprehensive genetic information on the potential therapeutic response (i.e. to targeted therapy, chemotherapy, immunotherapy)Incorporates pathway-based analysis for a holistic overview & therapeutic recommendations440 cancer-related genes (including 13 fusion genes)All types of solid tumors (lung, breast, colorectal, prostate, TNBC, pancreatic, ovarian, CCA, liver, glioblastoma, rare cancer, and other solid tumors)ACTHRD™:  Tumor tissue-based (FFPE)Determines BRCA 1/2, LOH, and HRD status for PARP inhibitor treatment24 HRR-related genes (including BRCA1/2)Ovarian cancer and HRD-/HRR-related cancer typesACTDrug® +:  Tumor tissue-based (FFPE)Focuses on clinically recommended biomarkers for targeted therapies40 actionable genes (including 13 fusion genes)Common cancer types: lung cancer, gastric cancer, colon cancer, prostate cancer, etc.ACTLung™: Tumor tissue-based (FFPE)Focuses on biomarkers associated with lung cancer for targeted therapy13 lung-cancer-related genes (including 8 fusion genes)Lung cancerACTMonitor® +:  Blood-based (ctDNA)Monitors disease burden and treatment response/resistance50 cancer-related genesSolid tumors (Pan-cancer)